文献速递先天性心脏病外科心外重症与机械循环支持

先天性心脏病患儿心脏移植后EBV相关PTLD风险增加

Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
PubMed 文献 · J Heart Lung Transplant · 2020-10-26

本研究分析了英国两家儿童心脏移植中心16年间200例<18岁患儿,比较先天性心脏病(CHD)与获得性心肌病(ACM)移植后PTLD风险。结果显示CHD和移植前EBV血清学阴性是PTLD独立危险因素,CHD患儿胸腺切除年龄更小且移植后2年及5年CD4+、CD8+ T淋巴细胞计数持续偏低。

要点

  • CHD是儿童心脏移植后PTLD的独立危险因素(调整HR 3.2)。
  • 移植前EBV血清学阴性亦独立增加PTLD风险(调整HR 2.7)。
  • CHD患儿胸腺切除年龄更小,移植后T细胞亚群持续偏低。

核心结论

  • 基础诊断CHD是儿童心脏移植后PTLD的独立危险因素,且与胸腺切除年龄更小相关。
  • CHD患儿移植后T淋巴细胞亚群持续改变可能损害对原发性EBV感染的反应,增加PTLD风险。

研究设计与样本

  • 回顾性队列研究,纳入英国两家儿童心脏移植中心16年间200例<18岁心脏移植患儿。
  • 采用Kaplan-Meier法评估无PTLD生存,Cox比例回归分析危险因素。

主要发现

  • 71例CHD患儿中17例发生PTLD,129例ACM患儿中18例发生PTLD。
  • 移植后5年全部PTLD累积发生率为21.1%。
  • 移植至PTLD发生的中位时间为2.9年(四分位距0.9-4.6)。
  • 移植前EBV血清学阴性(调整HR 2.7,95%CI 1.3-5.6,p=0.01)和基础诊断CHD(调整HR 3.2,95%CI 1.4-7.4,p=0.007)与PTLD风险升高独立相关。
  • CHD与ACM患儿胸腺切除年龄分别为0.4岁与5.5岁(p<0.01);移植后2年CHD患儿CD4+(391/µl vs 644/µl,p=0.01)和CD8+(382/µl vs 500/µl,p=0.01)T淋巴细胞计数显著低于ACM患儿。

临床怎么用

  • 对CHD心脏移植患儿应加强EBV监测和PTLD预警,尤其移植前EBV血清学阴性者。
  • 关注CHD患儿移植后T淋巴细胞亚群恢复情况,可能有助于评估PTLD风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children undergoing heart transplant are at higher risk of developing post-transplant lymphoproliferative disorder (PTLD) than other solid organ recipients. The factors driving that risk are unclear. This study investigated risk factors for PTLD in children transplanted at 1 of 2 United Kingdom pediatric cardiac transplantation centers. METHODS: All children (<18 years, n = 200) transplanted at our institution over a 16-year period were analyzed. Freedom from PTLD was assessed using the Kaplan-Meier method and Cox proportional regression. RESULTS: PTLD occurred in 17 of 71 children transplanted for congenital heart disease (CHD) and 18 of 129 transplanted for acquired cardiomyopathy (ACM). The cumulative incidence of all PTLD was 21.1% at 5 years after transplant. Median time from transplant to PTLD was 2.9 years (interquartile range: 0.9-4.6). Negative Epstein-Barr virus (EBV) serostatus pre-transplant (adjusted hazard ratio [HR]: 2.7, 95% CI: 1.3-5.6, p = 0.01) and underlying CHD (adjusted HR: 3.2, 95% CI: 1.4-7.4, p = 0.007) were independently associated with higher risk of PTLD. Age at thymectomy was significantly different between children with CHD and ACM (0.4 vs 5.5 years, p < 0.01). Median CD4+ and CD8+ T lymphocyte counts at 2 years after transplant were significantly lower in children transplanted for CHD vs ACM (CD4+: 391/µl vs 644/µl, p = 0.01; CD8+: 382/µl vs 500/µl, p = 0.01). At 5 years after transplant, those differences persisted among patients who developed PTLD (CD4+, 430/µl vs 963/µl, p < 0.01 and CD8+, 367/µl vs 765/µl, p < 0.01). CONCLUSION: Underlying CHD is an independent risk factor for PTLD and is associated with a younger age at thymectomy. A persistent association with altered T lymphocyte subsets may contribute to the impaired response to primary EBV infection and increase the risk of PTLD.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Offor UT, Bacon CM, Roberts J, et al. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children. J Heart Lung Transplant. 2020. PMID: 33339556. doi:10.1016/j.healun.2020.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。